Market Research

Avascular Necrosis Market Size,Share And Global Forecast 2032

Best Price Guarantee Length Publisher Published Date SKU
from $4,500 250 Pages Acumen Research and Consulting February, 2025 ACRC19659547
Best Price Guarantee
Price from $4,500
Length 250 Pages
Publisher Acumen Research and Consulting
Published Date February, 2025
SKU ACRC19659547

The Global Avascular Necrosis Market Size accounted for USD 671 Million in 2023 and is estimated to achieve a market size of USD 1,178.1 Million by 2032 growing at a CAGR of 6.6% from 2024 to 2032.

Avascular necrosis (AVN), also known as osteonecrosis, is a debilitating condition characterized by the death of bone tissue due to a lack of blood supply. The condition can lead to bone collapse, joint dysfunction, and severe pain, often requiring surgical intervention such as joint replacement or bone grafting. AVN typically affects the hip, knee, shoulder, and other weight-bearing joints, with the hip being the most commonly involved site. The global avascular necrosis market has seen significant advancements in its treatment options, driven by an increasing understanding of the disease, a growing aging population, and the rising incidence of conditions that contribute to AVN, such as trauma, corticosteroid use, alcohol consumption, and certain medical conditions like sickle cell anemia.

Avascular Necrosis Market Segmentation

The worldwide market for avascular necrosis is split based on disease type, treatment type, route of administration, diagnosis, sales channel, and geography.

Avascular Necrosis Disease Types

Traumatic Avascular Necrosis
Non-traumatic Avascular Necrosis

Avascular Necrosis Treatment Types

Drug Type
Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
Naproxen Sodium
Ibuprofen
Osteoporosis Drugs
Cholesterol Lowing Drugs
Blood Thinners
Others
Therapy
Physical Therapy
Exercises
Gene Therapy and Surgery

Avascular Necrosis Route of Administrations

Oral
Parenteral

Avascular Necrosis Diagnosis

MRI
CT Scan
Biopsy
PET and X-ray

Avascular Necrosis Sales Channels

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Avascular Necrosis Market Regional Outlook

North America

U.S.
Canada
Europe
U.K.
Germany
France
Spain
Rest of Europe
Asia-Pacific

India
Japan
China
Australia
South Korea
Rest of Asia-Pacific
Latin America

Brazil
Mexico
Rest of LATAM
The Middle East & Africa

South Africa
GCC Countries
Rest of the Middle East & Africa (ME&A)

Avascular Necrosis Market Players

Some of the top avascular necrosis companies offered in our report include Teva Pharmaceuticals Industries Ltd., GSK, Pfizer, Inc., Dr. Reddy’s Laboratories Ltd., Bayer AG, Alkem Labs, Novartis AG, Solara Active Pharma Sciences Limited., Rochem International, Inc., and Dwarkesh Pharmaceuticals Private Limited.


CHAPTER 1. Industry Overview of Avascular Necrosis Market
1.1. Definition and Scope
1.1.1. Definition of Avascular Necrosis
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Avascular Necrosis Market
1.2. Summary
CHAPTER 2. Research Approach
2.1. Methodology
2.2. Data Source
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.2. Restraints and Challenges
3.3. Growth Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Market Concentration Ratio and Market Maturity Analysis of Avascular Necrosis Market
3.6. Technological Roadmap for Avascular Necrosis Market
3.7. Value Chain Analysis
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2023
CHAPTER 4. Avascular Necrosis Market By Disease Type
4.1. Introduction
4.2. Avascular Necrosis Revenue By Disease Type
4.2.1. Avascular Necrosis Revenue (USD Million) and Forecast, By Disease Type, 2020-2032
4.2.2. Traumatic Avascular Necrosis
4.2.2.1. Traumatic Avascular Necrosis Market Revenue (USD Million) and Growth Rate (%), 2020-2032
4.2.3. Non-traumatic Avascular Necrosis
4.2.3.1. Non-traumatic Avascular Necrosis Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 5. Avascular Necrosis Market By Treatment Type
5.1. Introduction
5.2. Avascular Necrosis Revenue By Treatment Type
5.2.1. Avascular Necrosis Revenue (USD Million) and Forecast, By Treatment Type, 2020-2032
5.2.2. Drug Type
5.2.2.1. Drug Type Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
5.2.2.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.2.2. Naproxen Sodium
5.2.2.2.2.1. Naproxen Sodium Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.2.3 I buprofen
5.2.2.2.3.1 I buprofen Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.3. Osteoporosis Drugs
5.2.2.3.1. Osteoporosis Drugs Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.4. Cholesterol Lowing Drugs
5.2.2.4.1. Cholesterol Lowing Drugs Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.5. Blood Thinners
5.2.2.5.1. Blood Thinners Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.2.6. Others
5.2.2.6.1. Others Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.3. Therapy
5.2.3.1. Therapy Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.3.2. Physical Therapy
5.2.3.2.1. Physical Therapy Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.3.3. Exercises
5.2.3.3.1. Exercises Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.3.4. Gene Therapy and Surgery
5.2.3.4.1. Gene Therapy and Surgery Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 6. Avascular Necrosis Market By Route of Administration
6.1. Introduction
6.2. Avascular Necrosis Revenue By Route of Administration
6.2.1. Avascular Necrosis Revenue (USD Million) and Forecast, By Route of Administration, 2020-2032
6.2.2. Oral
6.2.2.1. Oral Market Revenue (USD Million) and Growth Rate (%), 2020-2032
6.2.3. Parenteral
6.2.3.1. Parenteral Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 7. Avascular Necrosis Market By Diagnosis
7.1. Introduction
7.2. Avascular Necrosis Revenue By Diagnosis
7.2.1. Avascular Necrosis Revenue (USD Million) and Forecast, By Diagnosis, 2020-2032
7.2.2. MRI
7.2.2.1. MRI Market Revenue (USD Million) and Growth Rate (%), 2020-2032
7.2.3. CT scan
7.2.3.1. CT scan Market Revenue (USD Million) and Growth Rate (%), 2020-2032
7.2.4. Biopsy
7.2.4.1. Biopsy Market Revenue (USD Million) and Growth Rate (%), 2020-2032
7.2.5. PET and X-ray
7.2.5.1. PET and X-ray Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 8. Avascular Necrosis Market By Sales Channel
8.1. Introduction
8.2. Avascular Necrosis Revenue By Sales Channel
8.2.1. Avascular Necrosis Revenue (USD Million) and Forecast, By Sales Channel, 2020-2032
8.2.2. Hospital Pharmacies
8.2.2.1. Hospital Pharmacies Market Revenue (USD Million) and Growth Rate (%), 2020-2032
8.2.3. Retail Pharmacies
8.2.3.1. Retail Pharmacies Market Revenue (USD Million) and Growth Rate (%), 2020-2032
8.2.4. Online Pharmacies
8.2.4.1. Online Pharmacies Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 9. North America Avascular Necrosis Market By Country
9.1. North America Avascular Necrosis Market Overview
9.2. U.S.
9.2.1. U.S. Avascular Necrosis Revenue (USD Million) and Forecast By Treatment Type, 2020-2032
9.2.2. U.S. Avascular Necrosis Revenue (USD Million) and Forecast By Disease Type, 2020-2032
9.2.3. U.S. Avascular Necrosis Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
9.2.4. U.S. Avascular Necrosis Revenue (USD Million) and Forecast By Diagnosis, 2020-2032
9.2.5. U.S. Avascular Necrosis Revenue (USD Million) and Forecast By Sales Channel, 2020-2032
9.3. Canada
9.3.1. Canada Avascular Necrosis Revenue (USD Million) and Forecast By Treatment Type, 2020-2032
9.3.2. Canada Avascular Necrosis Revenue (USD Million) and Forecast By Disease Type, 2020-2032
9.3.3. Canada Avascular Necrosis Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
9.3.4. Canada Avascular Necrosis Revenue (USD Million) and Forecast By Diagnosis, 2020-2032
9.3.5. Canada Avascular Necrosis Revenue (USD Million) and Forecast By Sales Channel, 2020-2032
9.4. North America PEST Analysis
CHAPTER 10. Europe Avascular Necrosis Market By Country
10.1. Europe Avascular Necrosis Market Overview
10.2. U.K.
10.2.1. U.K. Avascular Necrosis Revenue (USD Million) and Forecast By Treatment Type, 2020-2032
10.2.2. U.K. Avascular Necrosis Revenue (USD Million) and Forecast By Disease Type, 2020-2032
10.2.3. U.K. Avascular Necrosis Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
10.2.4. U.K. Avascular Necrosis Revenue (USD Million) and Forecast By Diagnosis, 2020-2032
10.2.5. U.K. Avascular Necrosis Revenue (USD Million) and Forecast By Sales Channel, 2020-2032
10.3. Germany
10.3.1. Germany Avascular Necrosis Revenue (USD Million) and Forecast By Treatment Type, 2020-2032
10.3.2. Germany Avascular Necrosis Revenue (USD Million) and Forecast By Disease Type, 2020-2032
10.3.3. Germany Avascular Necrosis Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
10.3.4. Germany Avascular Necrosis Revenue (USD Million) and Forecast By Diagnosis, 2020-2032
10.3.5. Germany Avascular Necrosis Revenue (USD Million) and Forecast By Sales Channel, 2020-2032
10.4. France
10.4.1 France Avascular Necrosis Revenue (USD Million) and Forecast By Treatment Type, 2020-2032
10.4.2 France Avascular Necrosis Revenue (USD Million) and Forecast By Disease Type, 2020-2032
10.4.3 France Avascular Necrosis Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
10.4.4 France Avascular Necrosis Revenue (USD Million) and Forecast By Diagnosis, 2020-2032
10.4.5 France Avascular Necrosis Revenue (USD Million) and Forecast By Sales Channel, 2020-2032
10.5 Spain
10.5.1 Spain Avascular Necrosis Revenue (USD Million) and Forecast By Treatment Type, 2020-2032
10.5.2 Spain Avascular Necrosis Revenue (USD Million) and Forecast By Disease Type, 2020-2032
10.5.3 Spain Avascular Necrosis Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
10.5.4 Spain Avascular Necrosis Revenue (USD Million) and Forecast By Diagnosis, 2020-2032
10.5.5 Spain Avascular Necrosis Revenue (USD Million) and Forecast By Sales Channel, 2020-2032
10.6 Rest of Europe
10.6.1 Rest of Europe Avascular Necrosis Revenue (USD Million) and Forecast By Treatment Type, 2020-2032
10.6.2 Rest of Europe Avascular Necrosis Revenue (USD Million) and Forecast By Disease Type, 2020-2032
10.6.3 Rest of Europe Avascular Necrosis Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
10.6.4 Rest of Europe Avascular Necrosis Revenue (USD Million) and Forecast By Diagnosis, 2020-2032
10.6.5 Rest of Europe Avascular Necrosis Revenue (USD Million) and Forecast By Sales Channel, 2020-2032
10.7 Europe PEST Analysis
CHAPTER 11 Asia Pacific Avascular Necrosis Market By Country
11.1 Asia Pacific Avascular Necrosis Market Overview
11.2 China
11.2.1 China Avascular Necrosis Revenue (USD Million) and Forecast By Treatment Type, 2020-2032
11.2.2 China Avascular Necrosis Revenue (USD Million) and Forecast By Disease Type, 2020-2032
11.2.3 China Avascular Necrosis Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
11.2.4 China Avascular Necrosis Revenue (USD Million) and Forecast By Diagnosis, 2020-2032
11.2.5 China Avascular Necrosis Revenue (USD Million) and Forecast By Sales Channel, 2020-2032
11.3 Japan
11.3.1 Japan Avascular Necrosis Revenue (USD Million) and Forecast By Treatment Type, 2020-2032
11.3.2 Japan Avascular Necrosis Revenue (USD Million) and Forecast By Disease Type, 2020-2032
11.3.3 Japan Avascular Necrosis Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
11.3.4 Japan Avascular Necrosis Revenue (USD Million) and Forecast By Diagnosis, 2020-2032
11.3.5 Japan Avascular Necrosis Revenue (USD Million) and Forecast By Sales Channel, 2020-2032
11.4 India
11.4.1 India Avascular Necrosis Revenue (USD Million) and Forecast By Treatment Type, 2020-2032
11.4.2 India Avascular Necrosis Revenue (USD Million) and Forecast By Disease Type, 2020-2032
11.4.3 India Avascular Necrosis Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
11.4.4 India Avascular Necrosis Revenue (USD Million) and Forecast By Diagnosis, 2020-2032
11.4.5 India Avascular Necrosis Revenue (USD Million) and Forecast By Sales Channel, 2020-2032
11.5 Australia
11.5.1 Australia Avascular Necrosis Revenue (USD Million) and Forecast By Treatment Type, 2020-2032
11.5.2 Australia Avascular Necrosis Revenue (USD Million) and Forecast By Disease Type, 2020-2032
11.5.3 Australia Avascular Necrosis Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
11.5.4 Australia Avascular Necrosis Revenue (USD Million) and Forecast By Diagnosis, 2020-2032
11.5.5 Australia Avascular Necrosis Revenue (USD Million) and Forecast By Sales Channel, 2020-2032
11.6 South Korea
11.6.1 South Korea Avascular Necrosis Revenue (USD Million) and Forecast By Treatment Type, 2020-2032
11.6.2 South Korea Avascular Necrosis Revenue (USD Million) and Forecast By Disease Type, 2020-2032
11.6.3 South Korea Avascular Necrosis Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
11.6.4 South Korea Avascular Necrosis Revenue (USD Million) and Forecast By Diagnosis, 2020-2032
11.6.5 South Korea Avascular Necrosis Revenue (USD Million) and Forecast By Sales Channel, 2020-2032
11.7 Rest of Asia-Pacific
11.7.1 Rest of Asia-Pacific Avascular Necrosis Revenue (USD Million) and Forecast By Treatment Type, 2020-2032
11.7.2 Rest of Asia-Pacific Avascular Necrosis Revenue (USD Million) and Forecast By Disease Type, 2020-2032
11.7.3 Rest of Asia-Pacific Avascular Necrosis Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
11.7.4 Rest of Asia-Pacific Avascular Necrosis Revenue (USD Million) and Forecast By Diagnosis, 2020-2032
11.7.5 Rest of Asia-Pacific Avascular Necrosis Revenue (USD Million) and Forecast By Sales Channel, 2020-2032
11.8 Asia Pacific PEST Analysis
CHAPTER 12 Latin America Avascular Necrosis Market By Country
12.1 Latin America Avascular Necrosis Market Overview
12.2 Brazil
12.2.1 Brazil Avascular Necrosis Revenue (USD Million) and Forecast By Treatment Type, 2020-2032
12.2.2 Brazil Avascular Necrosis Revenue (USD Million) and Forecast By Disease Type, 2020-2032
12.2.3 Brazil Avascular Necrosis Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
12.2.4 Brazil Avascular Necrosis Revenue (USD Million) and Forecast By Diagnosis, 2020-2032
12.2.5 Brazil Avascular Necrosis Revenue (USD Million) and Forecast By Sales Channel, 2020-2032
12.3 Mexico
12.3.1 Mexico Avascular Necrosis Revenue (USD Million) and Forecast By Treatment Type, 2020-2032
12.3.2 Mexico Avascular Necrosis Revenue (USD Million) and Forecast By Disease Type, 2020-2032
12.3.3 Mexico Avascular Necrosis Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
12.3.4 Mexico Avascular Necrosis Revenue (USD Million) and Forecast By Diagnosis, 2020-2032
12.3.5 Mexico Avascular Necrosis Revenue (USD Million) and Forecast By Sales Channel, 2020-2032
12.4 Rest of Latin America
12.4.1 Rest of Latin America Avascular Necrosis Revenue (USD Million) and Forecast By Treatment Type, 2020-2032
12.4.2 Rest of Latin America Avascular Necrosis Revenue (USD Million) and Forecast By Disease Type, 2020-2032
12.4.3 Rest of Latin America Avascular Necrosis Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
12.4.4 Rest of Latin America Avascular Necrosis Revenue (USD Million) and Forecast By Diagnosis, 2020-2032
12.4.5 Rest of Latin America Avascular Necrosis Revenue (USD Million) and Forecast By Sales Channel, 2020-2032
12.5 Latin America PEST Analysis
CHAPTER 13 Middle East & Africa Avascular Necrosis Market By Country
13.1 Middle East & Africa Avascular Necrosis Market Overview
13.2 GCC
13.2.1 GCC Avascular Necrosis Revenue (USD Million) and Forecast By Treatment Type, 2020-2032
13.2.2 GCC Avascular Necrosis Revenue (USD Million) and Forecast By Disease Type, 2020-2032
13.2.3 GCC Avascular Necrosis Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
13.2.4 GCC Avascular Necrosis Revenue (USD Million) and Forecast By Diagnosis, 2020-2032
13.2.5 GCC Avascular Necrosis Revenue (USD Million) and Forecast By Sales Channel, 2020-2032
13.3 South Africa
13.3.1 South Africa Avascular Necrosis Revenue (USD Million) and Forecast By Treatment Type, 2020-2032
13.3.2 South Africa Avascular Necrosis Revenue (USD Million) and Forecast By Disease Type, 2020-2032
13.3.3 South Africa Avascular Necrosis Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
13.3.4 South Africa Avascular Necrosis Revenue (USD Million) and Forecast By Diagnosis, 2020-2032
13.3.5 South Africa Avascular Necrosis Revenue (USD Million) and Forecast By Sales Channel, 2020-2032
13.4 Rest of Middle East & Africa
13.4.1 Rest of Middle East & Africa Avascular Necrosis Revenue (USD Million) and Forecast By Treatment Type, 2020-2032
13.4.2 Rest of Middle East & Africa Avascular Necrosis Revenue (USD Million) and Forecast By Disease Type, 2020-2032
13.4.3 Rest of Middle East & Africa Avascular Necrosis Revenue (USD Million) and Forecast By Route of Administration, 2020-2032
13.4.4 Rest of Middle East & Africa Avascular Necrosis Revenue (USD Million) and Forecast By Diagnosis, 2020-2032
13.4.5 Rest of Middle East & Africa Avascular Necrosis Revenue (USD Million) and Forecast By Sales Channel, 2020-2032
13.5 Middle East & Africa PEST Analysis
CHAPTER 14 Player Analysis Of Avascular Necrosis Market
14.1 Avascular Necrosis Market Company Share Analysis
14.2 Competition Matrix
14.2.1 Competitive Benchmarking of key players by price, presence, market share, and R&D investment
14.2.2 New Product Launches and Product Enhancements
14.2.3 Mergers And Acquisition In Global Avascular Necrosis Market
14.2.4 Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 15 Company Profile
15.1 Teva Pharmaceuticals Industries Ltd.
15.1.1 Company Snapshot
15.1.2 Business Overview
15.1.3 Financial Overview
15.1.3.1 Revenue (USD Million), 2023
15.1.3.2 Teva Pharmaceuticals Industries Ltd. 2023 Avascular Necrosis Business Regional Distribution
15.1.4 Product /Service and Specification
15.1.5 Recent Developments & Business Strategy
15.2 GSK
15.3 Pfizer, Inc.
15.4 Dr. Reddy’s Laboratories Ltd.
15.5 Bayer AG
15.6 Alkem Labs
15.7 Novartis AG
15.8 Solara Active Pharma Sciences Limited.
15.9 Rochem International, Inc.
15.10 Dwarkesh Pharmaceuticals Private Limited

$4,500
$7,000

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings